4CPS-134 Real-life effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia
Year: 2025
Type: conference-paper
Study design: Observational Study
Abstract: Background and Importance Hyperkalaemia is a common electrolyte disorder with potentially serious consequences in short, medium and long-term. Aim and Objectives To evaluate the real-life effectiveness of sodium zirconium cyclosilicate (SCZ) as a treatment for acute hyperkalaemia. Material and Methods Observational, retrospective, multidisciplinary study carried out in a tertiary hospital from December 2023 to February 2024. All hospitalised patients with SCZ prescriptions were included. Sociodemographic, clinical and analytical variables were collected, as well as doses of SCZ used, previous treatment with SCZ or calcium polystyrene sulfonate (CPS), and readmissions in the 30 days after discharge due to hyperkalaemia. The data were obtained from the electronic prescription programme and the electronic medical records. Results We included 60 patients, 66.7% men, median age 75±16.3 years, 55 (91.7%) had chronic kidney disease, 43 (78.2%) grade 4–5. Fourteen (23.3%) previously received haemodialysis (HD) or peritoneal dialysis; 23 (38.3%) were previously treated with SCZ and 10 (16.7%) with CPS. Forty-three (71.7%) presented hyperkalaemia during the admission, mean blood potassium value 5.82 mmol/L. A mean of 36.5 ±35 hours until normalising was necessary. Eight of them (18.6%) previously took SCZ. Four patients without previous HD (8.7%) needed a session to reduce potassium levels. Among the 37 patients who initiated SCZ during the admission, the most frequent initial dose was 10g/24h (37.8%), followed by 5g/24h (24.3%). Similarly, the most common maintenance dose was 10g/24h (35.1%), followed by 5g/24h (32.4%); five (13.5%) required no maintenance dose. At discharge, 22 (95.6%) out of 23 patients on previous SCZ treatment maintained it; only one discontinued treatment and continued with CPS. Among the 37 patients who initiated SCZ during the admission, 12 (32.4%) maintained it. The most common doses at discharge were 5g/24h (62.2%) and 10g/24h (18.9%). Five patients (8.3%) were readmitted with hyperkalaemia in the 30 days after discharge. In 4 (80%) SCZ had not been prescribed at discharge. Conclusion and Relevance SCZ is an effective drug to normalise potassium levels in an average of 36 hours. Less than 10% of patients without previous HD needed a session to normalise levels. Only one third of patients who started treatment maintain it at discharge References and/or Acknowledgements Conflict of Interest No conflict of interest
Institution: Hospital Universitario Ramón y Cajal
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4408375646